At a glance
ClinicalIndex Comparison RecordN/ACompleted· 45 enrolled
Drug / intervention
Lumositydevice
Likely dose
Lumosity neurocognitive training program (frequency and duration not specified)AI-extracted
Key inclusion· 3
- ✓Age 60–90 years
- ✓Scheduled for cardiac surgery at least 10 days from enrollment
- ✓High school education level or equivalent
Key exclusion· 6
- ✕Preexisting psychiatric illness
- ✕History of cerebrovascular event or seizure
- ✕Non-English speaking
- ✕Baseline severe cognitive dysfunction (Alzheimer's, Parkinson's, dementia)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevention of Early Postoperative Decline
In Brief
A clinical study evaluating Lumosity for Delirium and Postoperative Cognitive Dysfunction. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The purpose of this trial is to determine whether using a brain training program in the time leading up to as well as after heart surgery will reduce confusion and cognitive loss that can occur after surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDelirium, Postoperative Cognitive Dysfunction
CountriesUnited States
CollaboratorsLumos Labs, Inc.
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartNov 2016
Primary CompletionJan 2019
Study CompletionSep 2019
TodayJul 2026
First PostedSep 21, 2016
Enrollment StartNov 1, 2016
Primary CompletionJan 1, 2019
Study CompletionSep 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.8 years ago
Interventions
Lumositydevice
A neurocognitive training program designed to enhance cognitive abilities